Blueprint Medicines (BPMC) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 01/20/21
Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's WhyZacks Investment Research • 12/21/20
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid CancerPRNewsWire • 12/01/20
Was The Smart Money Right About Loading Up On Blueprint Medicines Corporation (BPMC)?Insider Monkey • 11/03/20
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/29/20
Blueprint Medicines (BPMC) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 10/29/20
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)Insider Monkey • 10/26/20
Blueprint European Approval, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 09/29/20
Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal TumorsPRNewsWire • 09/25/20
Blueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock JumpsInvestors Business Daily • 09/22/20
Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO™ (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid CancerPRNewsWire • 09/20/20
PANTHERx® Rare Pharmacy Selected by Blueprint Medicines to Distribute GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)PRNewsWire • 09/14/20
Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare ConferencePRNewsWire • 09/09/20
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung CancerPRNewsWire • 09/04/20
Why Is Blueprint Medicines (BPMC) Up 0.1% Since Last Earnings Report?Zacks Investment Research • 08/29/20